Oncoblaze
OncoBLAZE is dedicated to revolutionizing cancer treatment by developing precision-targeted therapies that eliminate residual cancer cells post-surgery. Their innovative technology focuses on preventing cancer recurrence through precise delivery of chemotherapy using triggered nanoparticles and proprietary imaging technology, aiming to improve patient outcomes and reduce healthcare costs.
Industries
Nr. of Employees
small (1-50)
Products
Real-time fluorescence imaging system for chemotherapy visualization
An imaging system designed to visualize fluorescence of chemotherapy released from thermosensitive nanoparticles during localized heating, enabling monitoring of spatial drug distribution and delivered dose in near real time.
Thermosensitive liposome-based drug-device prototype
A preclinical drug-device combination pairing thermosensitive liposomal chemotherapeutics with a precision heating device intended to trigger localized drug release at surgical cavities to eliminate residual cancer cells.
Real-time fluorescence imaging system for chemotherapy visualization
An imaging system designed to visualize fluorescence of chemotherapy released from thermosensitive nanoparticles during localized heating, enabling monitoring of spatial drug distribution and delivered dose in near real time.
Thermosensitive liposome-based drug-device prototype
A preclinical drug-device combination pairing thermosensitive liposomal chemotherapeutics with a precision heating device intended to trigger localized drug release at surgical cavities to eliminate residual cancer cells.
Services
Design and conduct of rodent/mouse tumor model studies to evaluate efficacy of thermosensitive nanoparticle drug delivery combined with localized heating.
Hardware and performance evaluation of fluorescence imaging systems, including limit-of-detection, spatial resolution, SNR, ambient-light operation, and benchmarking versus commercial platforms.
Joint research collaborations with universities and medical centers to advance technology development, preclinical testing, and translational planning.
Design and conduct of rodent/mouse tumor model studies to evaluate efficacy of thermosensitive nanoparticle drug delivery combined with localized heating.
Hardware and performance evaluation of fluorescence imaging systems, including limit-of-detection, spatial resolution, SNR, ambient-light operation, and benchmarking versus commercial platforms.
Joint research collaborations with universities and medical centers to advance technology development, preclinical testing, and translational planning.
Expertise Areas
- Image-guided drug delivery
- Thermosensitive liposomal drug delivery
- Localized hyperthermia-triggered release
- Preclinical in vivo efficacy testing
Key Technologies
- Thermosensitive liposomes
- Hyperthermia-triggered drug release
- Laser/electromagnetic localized hyperthermia
- Real-time fluorescence imaging
News & Updates
OncoBlaze was awarded a $50,000 federal grant from the South Carolina Research Authority to develop technologies targeting residual cancer cells after surgery.
OncoBLAZE showcased a new real-time fluorescence imaging system for visualizing chemotherapy delivery, enhancing precision in cancer treatment.
OncoBLAZE shared insights from their journey through the Innosphere Incubator, highlighting mentorship and industry connections.
A team from the Austrian Trade Commission visited OncoBLAZE to learn about their technology and explore collaborations.
OncoBLAZE participated in the ribbon-cutting for BlueSkyLabs and engaged with local officials to foster innovation.
The company received a grant to conduct preclinical studies in rodent models, supporting future clinical trials.
OncoBlaze was awarded a $50,000 federal grant from the South Carolina Research Authority to develop technologies targeting residual cancer cells after surgery.
OncoBLAZE showcased a new real-time fluorescence imaging system for visualizing chemotherapy delivery, enhancing precision in cancer treatment.
OncoBLAZE shared insights from their journey through the Innosphere Incubator, highlighting mentorship and industry connections.
A team from the Austrian Trade Commission visited OncoBLAZE to learn about their technology and explore collaborations.
OncoBLAZE participated in the ribbon-cutting for BlueSkyLabs and engaged with local officials to foster innovation.
The company received a grant to conduct preclinical studies in rodent models, supporting future clinical trials.